A Phase 3 interventional study of Tezepelumab and Budesonide/formoterol in Severe Asthma, sponsored by AstraZeneca. Active, not recruiting at 70 sites in 12 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.
Among the 28 studies testing tezepelumab in Asthma, this one is the 8th largest by enrollment, is the only one that started in 2024, is one of 16 in phase 3, and was the 22nd registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–55
AstraZeneca · Sites in China
Ages 12–80
AstraZeneca · Sites in United States, Argentina, Brazil and 19 more countries
Ages 5–11
Qianfoshan Hospital · Sites in China
Ages 18–75
Qilu Pharmaceutical Co., Ltd.
Ages 18–80
By country, each count listing its studies:
tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2024.
This study's enrollment of 310 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 121 across the 28 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 28 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 99th largest by enrollment of the 248 interventional ones that give a count, is one of 26 that started in 2024, is one of 121 in phase 3, reaches primary completion later than 7 of the 27 other live ones, and was the 326th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing tezepelumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06705764University of AlbertaTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | 2026-11 |
| NCT07757841Qianfoshan HospitalReal-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing tezepelumab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma..
Study details include:
This is a multicentre, randomised, open-label, parallel-group, phase IIIb study to assess the potential for tezepelumab-treated patients to (1) reduce maintenance therapy without the loss of asthma control at Week 56, among those who demonstrated asthma control or low biomarkers at Week 24, and (2) be in asthma control and have characteristics of clinical remission at Week 24.
Approximately 65 sites in 10 countries will enrol adult and adolescent patients with severe uncontrolled asthma.
The study is divided into 5 phases as described below:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Provision of signed and dated written ICF prior to any mandatory study-specific procedures, sampling, and analyses for patients who are at or over the age of majority (as per local law). For patients who are less than the age of majority, in addition to providing their informed consent, the patients' legally authorised representative must also provide their informed assent (Appendix A 3).
Age
Patients must be 12 to 80 years of age inclusive, at the time of signing the ICF.
Type of Patient and Disease Characteristics
Documented physician-diagnosed severe asthma within 10 years prior to Visit 1 (ie, severe asthma was not diagnosed more than 10 years prior) consisting of any of the following:
(i) Methacholine - PD20 ≤ 8 mg/mL (ii) Mannitol - PD15 15% drop on FEV1 out of dose \< than 635 mg of inhaled mannitol (iii) Exercise - 10% fall of FEV1
History of physician-diagnosed asthma that requires continuous treatment with high-dose ICS (as defined by GINA or highest approved dose per posology per country) plus a LABA for at least 6 months prior to Visit 1 (Appendix I). The ICS and LABA can be contained within a combination product or given by separate inhalers.
Note: Additional maintenance asthma controller medications (eg, LTRAs, tiotropium, cromone, theophylline) are allowed.
Documented history of at least one asthma exacerbation requiring OCS bursts or requiring hospitalization within 12 months prior to Visit 1. An asthma exacerbation will be defined as a worsening of asthma symptoms that leads to any of the following:
Sex and /Barrier Requirements
Male or female.
Female patients:
The following age-specific requirements apply:
WOCBP must be willing to use one of the methods of contraception described hereafter, from the time of signing the ICF throughout the study and 16 weeks after last tezepelumab administration:
Inclusion Criteria 5.1.2 Treatment Induction Phase at Visit 2 (Week 0):
Before dosing with tezepelumab at Week 0, patients should fulfil the following criteria:
Exclusion Criteria:
Medical Conditions
Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:
Evidence of COVID-19 within 4 weeks prior to screening or ongoing clinically significant COVID-19 sequelae.
Prior/Concomitant Therapy
Patients that have been treated with bronchial thermoplasty in the last 12 months prior to Visit 1.
Prior/Concurrent Clinical Study Experience
Concurrent enrolment in another clinical study involving an IMP.
Diagnostic Assessments
Positive surface antigen, virus antibody serology at screening, or a positive medical history for hepatitis B or C. Patients with a history of hepatitis B vaccination without a history of hepatitis B are allowed to participate.
Other Exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Asthma Control or Low Biomarkers - Step-down of ICS. Only patients with asthma control or low biomarkers at Week 24 will be randomized into Group 1 or 2
Combination Product: Tezepelumab · Combination Product: Budesonide/formoterol · Combination Product: Albuterol/budesonide (AIRSUPRA®) · Combination Product: Mannitol · Combination Product: Salbutamol
Asthma Control or Low Biomarkers - No Step-down of ICS. Only patients with asthma control or low biomarkers at Week 24 will be randomized into Group 1 or 2
Combination Product: Tezepelumab · Combination Product: Budesonide/formoterol · Combination Product: Albuterol/budesonide (AIRSUPRA®) · Combination Product: Mannitol · Combination Product: Salbutamol
No Asthma Control or Low Biomarkers - No Step-down of ICS
Combination Product: Tezepelumab · Combination Product: Budesonide/formoterol · Combination Product: Albuterol/budesonide (AIRSUPRA®) · Combination Product: Mannitol
IMP. Subcutaneous injection. Unit dose strengths 210 mg.
Also known as: TEZSPIRE®
Drug pages: Budesonide · Formoterol
AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation
Also known as: SYMBICORT® pMDI
Drug pages: Albuterol · Budesonide
AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.
Also known as: AIRSUPRA®
NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules
Also known as: ARIDOL®
AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation
Also known as: Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA
Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase.
Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase to either: Outside of the US: * Medium-dose maintenance and reliever therapy, or * Low-dose maintenance and reliever therapy, or * SYMBICORT® anti-inflammatory reliever only In the US: * Medium-dose SYMBICORT® and AIRSUPRA®,or * Low-dose SYMBICORT® and AIRSUPRA®, or * AIRSUPRA® only
Time frame: Week 56
Proportion of patients in asthma control
Proportion of patients in asthma control at Week24.
Time frame: Week 24
Proportion of patients with characteristics of clinical remission
Proportion of patients with characteristics of clinical remission at Week 24
Time frame: Week 24
Proportion of patients in asthma control at Week 56 among those in asthma control at Week 24
Proportion of patients in asthma control at Week 56 among those in asthma control at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.
Time frame: Week 56
Proportion of patients in asthma control at Week 72 among those in asthma control at Week 24
Proportion of patients in asthma control at Week 72 among those in asthma control at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.
Time frame: Week 72
Proportion of patients in asthma control at both Week 56 and Week 72 among those in asthma control at Week 24
Proportion of patients in asthma control at both Week 56 and Week 72 among those in asthma control at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.
Time frame: Week 56 and Week 72
Proportion of patients in asthma control at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24
Proportion of patients in asthma control at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24
Time frame: Week 56
Proportion of patients in asthma control at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24
Proportion of patients in asthma control at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24
Time frame: Week 72
Proportion of patients in clinical remission at Week 56 among those with characteristics of clinical remission at Week 24
Proportion of patients in clinical remission at Week 56 among those with characteristics of clinical remission at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.
Time frame: Week 56
Proportion of patients in clinical remission at Week 72 among those with characteristics of clinical remission at Week 24
Proportion of patients in clinical remission at Week 72 among those with characteristics of clinical remission at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.
Time frame: Week 72
Proportion of patients in clinical remission at both Week 56 and Week 72 among those with characteristics of clinical remission at Week 24
Proportion of patients in clinical remission at both Week 56 and Week 72 among those with characteristics of clinical remission at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.
Time frame: Week 56 and Week 72
Proportion of patients in clinical remission at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24
Proportion of patients in clinical remission at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24
Time frame: Week 56
Proportion of patients in clinical remission at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24
Proportion of patients in clinical remission at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24
Time frame: Week 72
Proportion of patients in complete remission at Week 56
Proportion of patients in complete remission at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: Week 56
Proportion of patients in complete remission at Week 72 among those in complete remission at Week 56
Proportion of patients in complete remission at Week 72 among those in complete remission at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: Week 72
Change from Week 24 at Week 56 in: ° Mean monthly maintenance ICS dose ° Mean monthly rescue ICS dose ° Mean monthly total ICS dose (maintenance and rescue doses)
Change from Week 24 at Week 56 in: * Mean monthly maintenance ICS dose * Mean monthly rescue ICS dose * Mean monthly total ICS dose (maintenance and rescue doses)
Time frame: From Week 24 at Week 56
Change from Week 24 at Week 72 in: ° Mean monthly maintenance ICS dose ° Mean monthly rescue ICS dose ° Mean monthly total ICS dose (maintenance and rescue doses)
Change from Week 24 at Week 72 in: * Mean monthly maintenance ICS dose * Mean monthly rescue ICS dose * Mean monthly total ICS dose (maintenance and rescue doses)
Time frame: From Week 24 at Week 72
Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 56
Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 56 both summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: Between Week 24 and Week 56
Cumulative daily ICS dose (maintenance and rescue doses) between Week 56 and Week 72
Cumulative daily ICS dose (maintenance and rescue doses) between Week 56 and Week 72 both summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: Between Week 56 and Week 72
Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 72
Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 72 both summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: Between Week 24 and Week 72
AAER between Week 0 and Week 24 among all tezepelumab-treated patients
Annualised Asthma Exacerbation Rate between Week 0 and Week 24 among all tezepelumab-treated patients.
Time frame: Between Week 0 and Week 24
AAER between Week 24 and Week 56
Annualised Asthma Exacerbation Rate between Week 24 and Week 56 summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: Between Week 24 and Week 56
AAER between Week 56 and Week 72
Annualised Asthma Exacerbation Rate between Week 56 and Week 72 summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: Between Week 56 and Week 72
AAER between Week 24 and Week 72
Annualised Asthma Exacerbation Rate between Week 24 and Week 72 summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: Between Week 24 and Week 72
ACQ-5 score and changes from baseline at Week 24 among all tezepelumab-treated patients
ACQ-5 score and changes from baseline at Week 24 among all tezepelumab-treated patients
Time frame: From baseline at Week 24
ACQ-5 score and changes from Week 24 at Week 56
ACQ-5 score and changes from Week 24 at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: From Week 24 at Week 56
ACQ-5 score and changes from Week 24 at Week 72
ACQ-5 score and changes from Week 24 at Week 72; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: From Week 24 at Week 72
Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from baseline at Week 24 among all tezepelumab-treated patients.
Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from baseline at Week 24 among all tezepelumab-treated patients.
Time frame: From baseline at Week 24
Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 56
Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: From Week 24 at Week 56
Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 72
Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 72; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: From Week 24 at Week 72
SGRQ total score and changes from baseline at Week 24 among all tezepelumab-treated patients.
SGRQ total score and changes from baseline at Week 24 among all tezepelumab-treated patients.
Time frame: From baseline at Week 24
SGRQ total score and changes from Week 24 at Week 56
SGRQ total score and changes from Week 24 at Week 56, summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: From Week 24 at Week 56
SGRQ total score and changes from Week 24 at Week 72
SGRQ total score and changes from Week 24 at Week 72, summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: From Week 24 at Week 72
Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from baseline at Week 24 among all tezepelumab-treated patients.
Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from baseline at Week 24 among all tezepelumab-treated patients
Time frame: From baseline at Week 24
Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 56
Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: From Week 24 at Week 56
Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 72
Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 72; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: From Week 24 at Week 72
Pre-BD FEV1 actual values and changes from baseline at Week 24 among all tezepelumab-treated patients.
Asthma exacerbations, patient-reported outcomes, and lung function. Pre-BD FEV1 actual values and changes from baseline at Week 24 among all tezepelumab-treated patients.
Time frame: Baseline at Week 24
Pre-BD FEV1 total score and changes from Week 24 at Week 56
Pre-BD FEV1 total score and changes from Week 24 at Week 56, summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24 among all tezepelumab-treated patients.
Time frame: From Week 24 at Week 56
Pre-BD FEV1 total score and changes from Week 24 at Week 72
Pre-BD FEV1 total score and changes from Week 24 at Week 72, summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24 among all tezepelumab-treated patients.
Time frame: From Week 24 at Week 72
Proportion of pre-BD FEV1 responders from baseline at Week 24
Proportion of pre-BD FEV1 responders from baseline (defined as patients who achieve either a≥ 5% or ≥ 100 mL improvement from baseline) at Week 24, for all tezepelumab-treated patients
Time frame: Week 24
Proportion of pre-BD FEV1 responders at Week 56 among those who were pre-BDFEV1 responders at Week 24
Proportion of pre-BD FEV1 responders at Week 56 among those who were pre-BDFEV1 responders at Week 24; summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: Week 56
Proportion of pre-BD FEV1 responders at Week 72 among those who were pre-BDFEV1 responders at Week 24
. Proportion of pre-BD FEV1 responders at Week 72 among those who were pre-BDFEV1 responders at Week 24; summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.
Time frame: Week 72
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Jun 2027, 32 months after the start.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 32 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab